Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Frontiers in Public Health
|
March 12, 2020
Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM
Gita A Toyserkani, Linda Huynh, Elaine H Morrato
BMC Health Services Research
|
August 7, 2021
Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018)
Linda Huynh, Gita A Toyserkani, Elaine H Morrato
Pharmaceutical Medicine
|
July 8, 2023
The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities
Gita A Toyserkani, Joann H Lee, Esther H Zhou
Drug Safety
|
March 24, 2026
US Risk Evaluation and Mitigation Strategies with Elements to Assure Safe Use: A Longitudinal Analysis of REMS Modifications (2008-2022)
Elaine H Morrato, Elizabeth J Campagna, Cynthia LaCivita, et al.
Drug Safety
|
September 11, 2023
Evolution of Cross-Sectional Survey Protocol Quality Over Time: A Case Series of Index U.S. REMS Knowledge Survey Protocols (2007-2020)
Gita A Toyserkani, Samuel B Ewusie, Philip Turk, et al.
Drug Safety
|
March 13, 2025
Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint
Meredith Y Smith, Rachel Davis, Priya Bahri, et al.
Drug Safety
|
November 27, 2025
Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials
Susan Chimonas, Carol Cosenza, Aaron S Kesselheim, et al.
Drug Safety
|
January 27, 2026
Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic
Catherine S Hwang, Zhigang Lu, Massimiliano Russo, et al.
Drug Safety
|
May 16, 2024
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020
Mufaddal Mahesri, Ameet Sarpatwari, Krista F Huybrechts, et al.
JAMA Network Open
|
February 13, 2025
Physician Experiences With and Perspectives on Clozapine Prescribing
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Frontiers in Public Health
|
March 12, 2020
Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM
Gita A Toyserkani, Linda Huynh, Elaine H Morrato
BMC Health Services Research
|
August 7, 2021
Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018)
Linda Huynh, Gita A Toyserkani, Elaine H Morrato
Pharmaceutical Medicine
|
July 8, 2023
The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities
Gita A Toyserkani, Joann H Lee, Esther H Zhou
Drug Safety
|
March 24, 2026
US Risk Evaluation and Mitigation Strategies with Elements to Assure Safe Use: A Longitudinal Analysis of REMS Modifications (2008-2022)
Elaine H Morrato, Elizabeth J Campagna, Cynthia LaCivita, et al.
Drug Safety
|
September 11, 2023
Evolution of Cross-Sectional Survey Protocol Quality Over Time: A Case Series of Index U.S. REMS Knowledge Survey Protocols (2007-2020)
Gita A Toyserkani, Samuel B Ewusie, Philip Turk, et al.
Drug Safety
|
March 13, 2025
Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint
Meredith Y Smith, Rachel Davis, Priya Bahri, et al.
Drug Safety
|
November 27, 2025
Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials
Susan Chimonas, Carol Cosenza, Aaron S Kesselheim, et al.
Drug Safety
|
January 27, 2026
Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic
Catherine S Hwang, Zhigang Lu, Massimiliano Russo, et al.
Drug Safety
|
May 16, 2024
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020
Mufaddal Mahesri, Ameet Sarpatwari, Krista F Huybrechts, et al.
JAMA Network Open
|
February 13, 2025
Physician Experiences With and Perspectives on Clozapine Prescribing
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, et al.
Page
of 2